BioNTech reported that BNT113, its messenger RNA therapy designed to train the immune system, failed to improve progression-free survival. The therapy was assessed as first-line treatment for patients with PD-L1-expressing head and neck squamous cell carcinoma linked to human papillomavirus 16. Roughly one in three cases of this cancer type is linked to HPV infection.
Researchers are continuing the study to determine whether BNT113 used with Keytruda can help patients live longer overall compared with Keytruda by itself. As BMO Capital Markets analyst Evan David Seigerman put it, "The treatment could still demonstrate an overall survival benefit, but we are more cautious on such a possibility." BioNTech said an early negative readout for therapies like this is not unusual because immune responses can evolve and strengthen over time, pointing to trials that initially missed the mark but later won approval, including Keytruda, "the world's top selling cancer medicine."
Trial failures reprice a biotech faster than almost any other event. Market Briefs covers that sector free every weekday.
The news marks a reverse for the German biotech; the company began with an oncology focus, despite achieving broad recognition through its Covid-19 vaccine. It also comes months after BioNTech and Roche Holding AG halted a study of a personalized cancer vaccine. Rivals have had brighter news: Moderna and Merck & Co. reported a study that reduced melanoma recurrence, a result viewed as a watershed moment. Traders took notice, with BioNTech's American depository receipts down as much as 6.1% in premarket action.
If you follow biotech, this is a reminder that pipelines are bumpy even for leaders. BioNTech still leans on mRNA as a pillar of its cancer strategy, and this trial now hinges on the overall survival readout. Between a recently scrapped personalized vaccine effort with Roche and a high-profile melanoma win for Moderna and Merck, the competitive stakes are shifting. For anyone tracking BioNTech exposure, the next catalyst is clear: whether BNT113 plus Keytruda ultimately moves the needle on survival.
Missing a primary endpoint changes the whole development path. Join Market Briefs free and follow it.
